Soliqua combination injection Solostar, manufactured by Sanofi, combines insulin glargine and lixisenatide to improve glycemic control in adults with type 2 diabetes. This combination medicine, with a YJ code of 3969501G1023 and a standard of 1 kit, is administered as a once-daily subcutaneous injection.
Soliqua combination injection Solostar
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →